Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04849273 |
|---|---|
| Brief Title: | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC |
| First Submitted : | April 12, 2021 |
| First Submitted that Met QC Criteria : | April 16, 2021 |
| First Posted : | April 19, 2021 |
| Last Update Submitted that Met QC Criteria : | November 7, 2022 |
| Last Update Posted : | November 8, 2022 |